Urra Félix A, Muñoz Felipe, Lovy Alenka, Cárdenas César
Anatomy and Developmental Biology Program, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
Geroscience Center for Brain Health and Metabolism, Santiago, Chile.
Front Oncol. 2017 Jun 8;7:118. doi: 10.3389/fonc.2017.00118. eCollection 2017.
Recent evidence highlights that the cancer cell energy requirements vary greatly from normal cells and that cancer cells exhibit different metabolic phenotypes with variable participation of both glycolysis and oxidative phosphorylation. NADH-ubiquinone oxidoreductase (Complex I) is the largest complex of the mitochondrial electron transport chain and contributes about 40% of the proton motive force required for mitochondrial ATP synthesis. In addition, Complex I plays an essential role in biosynthesis and redox control during proliferation, resistance to cell death, and metastasis of cancer cells. Although knowledge about the structure and assembly of Complex I is increasing, information about the role of Complex I subunits in tumorigenesis is scarce and contradictory. Several small molecule inhibitors of Complex I have been described as selective anticancer agents; however, pharmacologic and genetic interventions on Complex I have also shown pro-tumorigenic actions, involving different cellular signaling. Here, we discuss the role of Complex I in tumorigenesis, focusing on the specific participation of Complex I subunits in proliferation and metastasis of cancer cells.
最近的证据表明,癌细胞的能量需求与正常细胞有很大差异,并且癌细胞表现出不同的代谢表型,糖酵解和氧化磷酸化的参与程度各不相同。NADH-泛醌氧化还原酶(复合体I)是线粒体电子传递链中最大的复合体,为线粒体ATP合成所需的质子动力提供约40%的贡献。此外,复合体I在癌细胞增殖、抗细胞死亡和转移过程中的生物合成和氧化还原控制中起着至关重要的作用。尽管关于复合体I的结构和组装的知识不断增加,但关于复合体I亚基在肿瘤发生中的作用的信息却很少且相互矛盾。几种复合体I的小分子抑制剂已被描述为选择性抗癌剂;然而,对复合体I的药理学和基因干预也显示出促肿瘤作用,涉及不同的细胞信号传导。在这里,我们讨论复合体I在肿瘤发生中的作用,重点关注复合体I亚基在癌细胞增殖和转移中的具体参与情况。